Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: The relevance of apolipoprotein E genotypes and immunological status

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 5, 2004, Pages 525-532

  Malavazi, Iran ^a   Abrão, Emiliana P ^a   Mikawa, Angela Y ^a   Landgraf, Viviane O ^a   da Costa, Paulo Inácio ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

apoE polymorphism; Apolipoprotein E (apoE); CD4+ lymphocytes; Coronary artery disease; Highly active antiretroviral therapy (HAART); HIV

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL PAIN; ADULT; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; BRAZIL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE STATUS; LIPID METABOLISM; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREDICTION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BRAZIL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CLINICAL PROTOCOLS; FEMALE; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; MALE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; TRIGLYCERIDES;

EID: 2942693714     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.089     Document Type: Article

References (51)

1. Clumeck N, Wit SD. Update on highly active antiretroviral therapy: progress and strategies. Biomed Pharmacother 2000;54:7-12.
2. Carr A, Samarras K, Burthon S, Law M, Freund J, Chirsholm DJ, et al. A syndrome of peripheral lipodistrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-8.
3. Carr A, Samaras H, Chirholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodistrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
4. Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 1998;352:881-2.
5. Carr A. HIV protease inhibitor-induced lipodystrophy syndrome. AIDS Rev 1999;1:29-36.
6. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;17:700-5
7. Thiébaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercé P, Daoucourt V, et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine cohort, France, 1996 to 1998. J Acqir Immune Def Synd 2000;23:261-5.
8. Tsiodras S, Mantozoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - a five-year cohort study. Arch Intern Med 2000;160:2050-6.
9. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001;4:99-103.
10. Behrens G, Schmidt HH, Stoll M, Schmidt RE. Apo E genotype and protease-inhibitor-associated hyperlipidemia. Lancet 1999;354:76.
11. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A,Massip, P et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15:2397-406.
12. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999;29:441-3.
13. Purnell JQ, Zambon A, Knopp RH, Pizzuti DL, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-7.
14. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
15. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20.
16. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson R. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
17. 2 in HIV-1 infection. Thromb Res 1996;81:213-8.
18. Shor-Posner G, Bassit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early immunodeficiency virus-1 infection. Am J Med 1993;94:515-9.
19. Grunfeld C, Doerrler W, Pang M, Jensen P, Weisgraber KH, Feingold KR. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997;82:3734-40.
20. Vella E, Palmisano L. Antiretroviral therapy: state of the HAART. Antivir Res 2000;45:1-7.
21. Winkelmann B, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ. Genetics of coronary heart disease: current knowledge and research principles. Am Heart J 2000;140:S11-S26.
22. Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta 1996;246:21-38.
23. Ozturk IC, Killeen A. An overview of genetic factors influencing plasma lipid levels and coronary artery disease risk. Arch Pathol Lab Med 1999;123:1219-22.
24. Siest G, Pillot T, Régis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, et al. Apolipoprotein E: an important gene to follow in laboratory medicine. Clin Chem 1995;41:1068-86.
25. Brower DAJ, Van Doormaal JJ, Muskiet FAJ. Clinical chemistry of common apolipoprotein E isoforms. J Chromatogr B Biomed Appl 1996;678:23-41.
26. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999;286:115-43.
27. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
28. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989;341:162-4.
29. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779-84.
30. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
31. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
32. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545-8.
33. Rosner B. Fundamentals of biostatistics, 4th ed. California: Duxburry Press, 1995.
34. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csázár A, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991;49:338-49.
35. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U. Ehnholm C, Evans A, et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope project. Atherosclerosis 2000;152:477-88.
36. Cavalli SA, Otta MI, Hirata RDC, Nguyen NY, Hirata MH. Apolipoprotein E genotyping in Brazilian normolipemic individuals [abstract]. Clin Chem 1996;42:S298.
37. Otta MI, Cavalli SA, Hirata RDC, Lottenberg S, Quintão E, Hirata MH. Apolipoprotein E genotype frequencies in hypercholesterolemic and diabetic individuals [abstract]. Clin Chem 1996;42:S297.
38. Salazar LA, Hirata MH, Gianini SD, Forti N, Diament J, Lima TM, et al. Seven DNA polymorphisms at the candidate of atherosclerosis in Brazilian women with angiographically documented coronary artery disease. Clin Chim Acta 2000;300:139-49.
39. Fernández-Miranda C, Pulido F, Carrillo JL, Larumbe S, Isquierdo TG, Ortuño B, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998;274:63-70.
40. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;246:567-75.
41. Fessel JW, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002;16:1785-9.
42. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus and lipodystrophy. Clin Infect Dis. 2001;32:130-9.
43. Stein HJ, Klein M, Bellehumeur JL, McBrid PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;17:257-62.
44. Lamarche B, Rashid S, Lewis GF. HDL metabolism on hypertriglyceridemic states: an overview. Clin Chim Acta 1999;286:145-61.
45. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglycericle enrichment and elevated hepatic lipase activity. Clin Biochem 2003;36:421-9.
46. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol. 2002;22:667-73.
47. Johnson DB, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women. Circulation 2004;109:726-32.
48. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid a during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000;20:763-72.
49. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
50. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, et al. HIV protease inhibitors protect apolipoprotein B from degradation by proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-31.
51. Levi GC, Vitória MAA. Fighting against AIDS: the Brazilian experience. AIDS 2002;16:2373-83.